Progenika Biopharma
Contact information
Progenika Biopharma, SA
Sergio Escorza, Director de Alianzas Estratégicas Internacionales
Parque Tecnológico de Bizkaia
Derio
Bizkaia
944064525
944064526
Areas of activities
- A. Health Biotechnology
- Areas of activity
- Biodrugs
- In vitro diagnostics
- Therapeutic areas
- Analgesia & Pain
- Dermatology
- Cardiovascular diseases and circulatory system
- Genetic and rare diseases
- Infectious diseases
- Inflammatory diseases
- Immunology
- Ophtalmology and optometry
- Oncology
- Blood and lymphatic system
- Digestive system and hepatology
- Kidney and genitourinary system
- Central nervous system
- Metabolic disorders / Endocrinology
- C. Industrial Biotechnology
- Manufacture of biotech equipment
- D. Services
- R&D services
- Bioinformatics
- Biotechnolgy kits
- Genomics
- Metabolomics
- Proteomics
- Professional services
- Consultancy
Commissions
Progenika´s mission is to improve healthcare through the development, validation and commercialization of products that allow personalization of treatment for complex diseases: in vitro tests for their prevention, diagnosis and prognosis; prediction of response to drugs; and monitoring of the effectiveness of biologic therapies.
Products and services
Areas of expertise and interest for Progenika Group companies include:
- Genotyping: Testing based on SNPs is applicable to a broad spectrum of studies, such as the identification of diseases and etiological research, gene association, mutational analyses, or associations between disease and gain/loss of chromosomal regions.
- Massive sequencing: de novo and re-sequencing technologies allow gathering significant gene functional information, offering a high capacity and data quality unattainable by traditional sequencing.
- Analyses of gene expression: our platforms make it possible to analyze simultaneously, in a quantitative and reproducible way, the expression levels of thousands of genes involved in a particular physiological process. Projects aimed at a restricted number of candidate genes and/or validation of expression markers is also possible.
- Non-coding RNA: the large number of genes regulated by microRNAs makes the analysis of this kind of molecules particularly interesting to identify those that are associated with different pathologies.
- Gene regulation: there are several technological options for the analysis of regulatory mechanisms, from massive sequencing studies applied to analysis of methylation to specific studies using microarrays.
- Production of solid and liquid microarrays and immunoassays: tests for the detection of proteomic and genomic biomarkers can be implemented in different formats, such as ELISAs, chips, or liquid arrays based on suspended microspheres or microparticles.tion sequencing; or solid array, liquid array and immunoassay development
Biotech Sanitaria
| Product / Service | Type | Therapeutic area | Aplication | Development phase |
|---|---|---|---|---|
| SEQPROLIPO IS | Diagnostic | Others breeding techniques (molecular markers, ...) | SEQPRO LIPO IS is a polymerase chain reaction (PCR) based assay to be used in a Next Generation Sequencing protocol for the detection of variants associated with Autosomal Dominant Hypercholesterolemia (ADH) and Autosomal Recessive Hypercholesterolemia (ARH). This assay was developed for use with genomic DNA extracted from whole blood specimens collected in EDTA. | Registration |
| A1AT GENOTYPING TEST | Diagnostic | Others breeding techniques (molecular markers, ...) | Genetic testing reagents for qualitative detection of specific allelic variants based on Polymerase Chain Reaction (PCR) and Luminex xMAP Technology, using genomic DNA samples. | Registration |
| ID RHD XT | Diagnostic | Sangre y sistema linfático | "ID RHD XT is a qualitative, PCR-based and hybridization-based genotyping test for the simultaneous identification of six alleles of the RHD gene and two alleles of the ITGB3 gene in genomic DNA extracted from whole blood specimens collected in EDTA. This test can be used to type the following allelic variants of the RHD gene: RHD*weak D type 1, RHD*weak D type 2, RHD*weak D type 3, RHD deletion, RHD*Pseudogene and RHD*DIIIa-CE(3-7)-D and ITGB3 gene (HPA-1 system): HPA1a and HPA1b. ID RHD XT can be used to genotype and predict Rh and HPA-1 phenotypes in patients and/or blood donors. The product is intended for professional use in a laboratory environment. The genotypes and predicted phenotype results will be reported from the combination of the allelic variants tested. The RHD predicted phenotype result should be always interpreted within the clinical context and serology data. ID RHD XT ANALYSIS SOFTWARE is a qualitative software application designed to transform Luminex system (Luminex 200 or FLEXMAP 3D) readings (CSV output) from Progenika Biopharma´s ID RHD XT assay into a genotype and predicted phenotype for each of the blood group systems analyzed in the assay. The product is intended for professional use in a laboratory environment" | Registration |
| ID HPA XT | Diagnostic | Sangre y sistema linfático | ID HPA XT is a qualitative, PCR-based and hybridization-based genotyping test for the simultaneous identification of multiple alleles encoding human platelet antigens (HPA) in genomic DNA extracted from whole blood specimens collected in EDTA. This test can be used to type allelic variants that determine the following human platelet antigens: HPA-1, HPA-2, HPA-3, HPA-4, HPA-5, HPA-6, HPA-7, HPA-8, HPA-9, HPA-10, HPA-11, and HPA-15. ID HPA XT™ analyzes 13 polymorphisms determining 18 antigens of the aforementioned human platelet antigens. This ID HPA XT can be used to genotype and predict the Human Platelet Antigens (HPA) phenotype in patients, and/or blood donors. The product is intended for professional use in a laboratory environment. ID HPA XT ANALYSIS SOFTWARE is a qualitative software application designed to transform Luminex 200 system readings (CSV output) from Progenika Biopharma´s ID HPA XT assay into a genotype and predicted phenotype for each of the human platelet antigen (HPA) analyzed in the assay. The product is intended for professional use in a laboratory environment | Registration |
| ID CORE CONTROL | Diagnostic | Sangre y sistema linfático | The ID CORE CONTROL kit contains two separate vials: ID CORE CONTROL 1 and ID CORE CONTROL 2, both composed of synthetic plasmid pools to be used as assayed positive controls for alternate alleles (alleles 1 and 2) of the 29 polymorphisms interrogated by ID CORE XT. ID CORE CONTROL samples are not intended to monitor the DNA extraction step of the ID CORE XT processing protocol. The product is intended for professional use in a laboratory environment | Registration |
| ID CORE XT | Diagnostic | Sangre y sistema linfático | ID CORE XT is a qualitative, PCR-based and hybridization-based genotyping test for the simultaneous identification of multiple alleles encoding human erythrocyte antigens (HEAs) in genomic DNA extracted from whole blood specimens collected in EDTA. The test interrogates 29 polymorphisms for 53 HEA Alleles and 37 Antigens prediction of the blood group systems Rh, Kell, Kidd, Duffy, MNS, Diego, Dombrock, Colton, Cartwright, and Lutheran, as an alternative to serology. ID CORE XT can be used to genotype and predict the Red Blood Cells (RBC) phenotype in patients and/or blood donors. The product is intended for professional use in a laboratory environment. ID CORE XT ANALYSIS SOFTWARE is a qualitative software application designed to transform Luminex system (Luminex 200 or FLEXMAP 3D) readings (CSV output) from Progenika Biopharma´s ID CORE XT assay into a genotype and predicted phenotype for each of the blood group systems analyzed in the assay. The product is intended for professional use in a laboratory environment | Registration |
| Promonitor QUICK - PoC | Diagnostic | Inmunología | Rapid immunochromatography test based on the quantitative detection of therapeutic drugs or the qualitative detection of anti-drug antibodies in human whole blood or serum | Registration |
| Promonitor - ELISA | Patient Monitoring Equipment | Inmunología | Promonitor devices are in vitro diagnostic tests to be used in laboratories for the Therapeutic Drug Monitoring (TDM) of a series of biological therapies for the treatment of inflammatory diseases. TDM applied to biological therapies is defined as the measurement of Drug Levels (DL) and Anti-Drug Antibodies (ADA) levels to aid in the management of patients. TDM is widely available in patients with inflammatory bowel diseases (IBD), which include Crohn’s disease (CD) and ulcerative colitis (UC), and to a lesser extent in rheumatic conditions like Rheumatoid Arthritis (RA), spondyloarthritis, ankylosing spondylitis, among others, and dermatology (psoriasis). Biological drugs covered by the Promonitor product line are: Infliximab, Adalimumab, Golimumab, Etanercept, Rituximab, Vedolizumab and Ustekinumab) | Registration |